Live COVID-19 Cases
  • World 354,664,830
    Confirmed: 354,664,830
    Active: 67,415,504
    Recovered: 281,627,475
    Death: 5,621,851
  • USA 72,624,726
    Confirmed: 72,624,726
    Active: 27,039,699
    Recovered: 44,693,753
    Death: 891,274
  • India 39,543,328
    Confirmed: 39,543,328
    Active: 2,249,287
    Recovered: 36,804,145
    Death: 489,896
  • Brazil 24,134,946
    Confirmed: 24,134,946
    Active: 1,659,612
    Recovered: 21,851,922
    Death: 623,412
  • France 16,800,913
    Confirmed: 16,800,913
    Active: 6,211,015
    Recovered: 10,460,876
    Death: 129,022
  • UK 15,953,685
    Confirmed: 15,953,685
    Active: 3,394,801
    Recovered: 12,404,968
    Death: 153,916
  • Russia 11,173,300
    Confirmed: 11,173,300
    Active: 801,197
    Recovered: 10,045,336
    Death: 326,767
  • Italy 10,001,344
    Confirmed: 10,001,344
    Active: 2,709,857
    Recovered: 7,147,612
    Death: 143,875
  • Spain 9,280,890
    Confirmed: 9,280,890
    Active: 3,562,883
    Recovered: 5,626,013
    Death: 91,994
  • Germany 8,808,107
    Confirmed: 8,808,107
    Active: 1,417,492
    Recovered: 7,273,100
    Death: 117,515
  • China 105,660
    Confirmed: 105,660
    Active: 2,754
    Recovered: 98,270
    Death: 4,636
Generic selectors
Exact matches only
Search in title
Search in content
Generic selectors
Exact matches only
Search in title
Search in content
Three Black and disabled folx (a non-binary person in a power wheelchair, a femme leaning against a wall, and a non-binary person standing with a cane) engaged in conversation. All three are outdoors and in front of a building with two large windows.

BY Leo Hynett


Sickle Cell Patients Still Not Eligible for Free Prescriptions

Despite the lifelong need for medication, sickle cell patients must pay for NHS prescriptions. There is, however, an easy way to pay considerably less.

DECEMBER 16  2021


The All-Party Parliamentary Group on Sickle Cell and Thalassaemia (SCTAPPG) recently launched an inquiry into the avoidable deaths and failures of care for sickle cell patients in secondary care. Succinctly titled No One’s Listening, the inquiry is a call to action in response to the unnecessary deaths in the sickle cell community and institutional racism that is present in healthcare, affecting everything from attitudes of staff to prescription charges. With over 100 submissions from the community, this is the most comprehensive report on sickle cell care that the APPG has ever produced.

No One’s Listening was the focus of the Treatment of Sickle Cell debate at Westminster Hall, where MPs were quizzed about whether SCD would be added to the Medical Exemptions list. If SCD were added to this list, patients could get their prescriptions for free. This is not a new suggestion – over two years ago Janet Darby (MP) asked the then Health Secretary Matt Hancock to remove the charge, but no progress has been made.

The cost of care

Most healthcare is completely free under the NHS but, unless you are exempt, you must pay a small charge for prescription medication. This charge may be small but, if you’re taking five different medications a day for a lifelong condition, £9.35 per prescription adds up fast.

However, if you are regularly taking medication and it is costing you more than £100 a year – which SCD medication likely is – a Prescription Prepayment Certificate (PPC) will quickly save you money. A PPC is £108.10 for 12 months, lets you get as many NHS prescriptions as you need, and can be applied for online.

This certificate is not something many people know about, which is something that urgently needs to change; when paying for individual prescriptions, some sickle cell patients can spend over the cost of a yearly PPC on a single month’s medication. One patient we spoke to was stunned when she found out how much she could have saved over the years if she’d been made aware of PPCs. When a GP is prescribing such a large amount of medication to a patient it would be pertinent to mention the availability of a PPC.

Although this price is massively reduced from paying per prescription – it works out at as little as £2 per week – questions remain around why people with SCD should have to pay for such necessary medication at all. Hydroxyurea – until recently the only licensed treatment for sickle cell in the UK – is free for cancer patients but not for people with sickle cell. SCD patients having to pay for prescriptions is perhaps emblematic of a wider issue.

Institutional racism

Questions have arisen surrounding why SCD is not on the Medical Exemptions list when other conditions such as epilepsy are. It has been suggested that this is a result of who the condition affects – epilepsy disproportionately affects white people whereas SCD disproportionately affects BAME people. ‘I don’t understand how the government can so frequently challenge the existence of institutional racism whilst charging those with sickle cell for prescriptions,’ commented one MP.

Much like prescriptions, admissions to hospital are not one-offs for people with SCD; it’s a lifelong part of living with the condition. Due to inadequate – or non-existent – community care, hospitalisations are far more frequent than they need to be and the understanding of SCD in these settings remains limited. From biased perceptions of pain tolerance to implications that patients are simply ‘drug seekers’, there are a lot of institutional barriers to SCD patients receiving adequate care.

In the Treatment of Sickle Cell debate, Labour MP Catherine West noted that ‘despite this being a long-running disease, we have not paid enough attention to it at an institutional level, be that in primary or secondary care. That needs urgent redress.’

SCD is often described as an invisible illness due to the fact the pain patients experience isn’t visible to others. But, perhaps if there was greater awareness of the condition among medical staff and the general public, it would not be so invisible after all.

Recommended for you

Modelling the Potential Consequences of Omicron

Analysing the impact mask-wearing has on Omicron hospital admissions, and whether the public’s choices can change the outcome.

Minesto: Revolutionising Ocean Energy

Minesto: Revolutionising Ocean Energy

Through their innovative tech, Swedish company Minesto leverages the power generated from underwater ‘kites’ as a source of renewable energy.